Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Vijaya Bharti"'
Autor:
Roman Uzhachenko, Sangeetha M Reddy, Ann Richmond, Amrendra Kumar, Vijay Ramani, Vijaya Bharti, Daniel de Lima Bellan, Nabil Saleh, Chengli Shen, Carlos Arteaga, Anna Vilgelm
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 5 (2023)
Background Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy are a mainstay treatment for hormone receptor-positive breast cancer. While their principal mechanism is inhibition of cancer cell proliferation, preclinical
Externí odkaz:
https://doaj.org/article/13820c3a95cc4295865abab27412d7b2
Publikováno v:
Journal of Laboratory Physicians, Vol 11, Iss 03, Pp 275-280 (2019)
BACKGROUND: The contamination with Entamoeba histolytica, Giardia lamblia, and Salmonella spp. in drinking water is the most prevalent in Indian subcontinent, but often difficult to detect all these pathogens from the drinking water. MATERIALS AND ME
Externí odkaz:
https://doaj.org/article/71101c7370c84ffab923d502fba8fd00
Autor:
Roman V. Uzhachenko, Vijaya Bharti, Zhufeng Ouyang, Ashlyn Blevins, Stacey Mont, Nabil Saleh, Hunter A. Lawrence, Chengli Shen, Sheau-Chiann Chen, Gregory D. Ayers, David G. DeNardo, Carlos Arteaga, Ann Richmond, Anna E. Vilgelm
Publikováno v:
Cell Reports, Vol 35, Iss 1, Pp 108944- (2021)
Summary: Inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6i) delay progression of metastatic breast cancer. However, complete responses are uncommon and tumors eventually relapse. Here, we show that CDK4/6i can enhance efficacy of T cell-based t
Externí odkaz:
https://doaj.org/article/79f5d8debd9044078fe632ac824c4fe3
Autor:
Kensey Bergdorf, Courtney Phifer, Vijaya Bharti, David Westover, Joshua Bauer, Anna Vilgelm, Ethan Lee, Vivian Weiss
Publikováno v:
STAR Protocols, Vol 1, Iss 3, Pp 100212- (2020)
Summary: Generation of fine-needle aspiration (FNA)-derived cancer organoids has allowed us to develop a number of downstream applications. In this protocol, we start with organoids cultured in a semi-solid format. We dissociate organoids into single
Externí odkaz:
https://doaj.org/article/9eee8907104c4e6b98362bd9f4ffe660
Autor:
Anna E. Vilgelm, Kensey Bergdorf, Melissa Wolf, Vijaya Bharti, Rebecca Shattuck-Brandt, Ashlyn Blevins, Caroline Jones, Courtney Phifer, Mason Lee, Cindy Lowe, Rachel Hongo, Kelli Boyd, James Netterville, Sarah Rohde, Kamran Idrees, Joshua A. Bauer, David Westover, Bradley Reinfeld, Naira Baregamian, Ann Richmond, W. Kimryn Rathmell, Ethan Lee, Oliver G. McDonald, Vivian L. Weiss
Publikováno v:
iScience, Vol 23, Iss 8, Pp 101408- (2020)
Summary: Patient-derived cancer organoids hold great potential to accurately model and predict therapeutic responses. Efficient organoid isolation methods that minimize post-collection manipulation of tissues would improve adaptability, accuracy, and
Externí odkaz:
https://doaj.org/article/8afed6fb0a4e4ebb9491411bebb640fc
Autor:
Ann Richmond, Anna E. Vilgelm, Douglas B. Johnson, Ana Grau, Mary Hooks, Rondi M. Kauffmann, Mark C. Kelley, Chi Yan, Gregory D. Ayers, Kimberly B. Dahlman, Vijaya Bharti, Caroline A. Nebhan, Rami Nayef Al-Rohil, Jamye F. O'Neal, Holly Crandall, Christopher Andrew Johnson, Emily Murray, Sheau-Chiann Chen, Rebecca L. Shattuck-Brandt
Supplementary Figure S3: Alterations in Protein Expression Associated with D+T Response in Group I PDX lines.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a615a26d692e75ec4c67385d90b7ac58
https://doi.org/10.1158/1078-0432.22468085.v1
https://doi.org/10.1158/1078-0432.22468085.v1
Autor:
Ann Richmond, Anna E. Vilgelm, Douglas B. Johnson, Ana Grau, Mary Hooks, Rondi M. Kauffmann, Mark C. Kelley, Chi Yan, Gregory D. Ayers, Kimberly B. Dahlman, Vijaya Bharti, Caroline A. Nebhan, Rami Nayef Al-Rohil, Jamye F. O'Neal, Holly Crandall, Christopher Andrew Johnson, Emily Murray, Sheau-Chiann Chen, Rebecca L. Shattuck-Brandt
Supplementary Table S1. A. NGS Summary.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c7faf68099ece8781e0a728803768d5
https://doi.org/10.1158/1078-0432.22468076.v1
https://doi.org/10.1158/1078-0432.22468076.v1
Autor:
Ann Richmond, Anna E. Vilgelm, Douglas B. Johnson, Ana Grau, Mary Hooks, Rondi M. Kauffmann, Mark C. Kelley, Chi Yan, Gregory D. Ayers, Kimberly B. Dahlman, Vijaya Bharti, Caroline A. Nebhan, Rami Nayef Al-Rohil, Jamye F. O'Neal, Holly Crandall, Christopher Andrew Johnson, Emily Murray, Sheau-Chiann Chen, Rebecca L. Shattuck-Brandt
Purpose:Over 60% of patients with melanoma respond to immune checkpoint inhibitor (ICI) therapy, but many subsequently progress on these therapies. Second-line targeted therapy is based on BRAF mutation status, but no available agents are available f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::878b6ec941e09bff49ae82d864b61c19
https://doi.org/10.1158/1078-0432.c.6526829
https://doi.org/10.1158/1078-0432.c.6526829
Autor:
Amrendra Kumar, Vijay Ramani, Vijaya Bharti, Daniel de Lima Bellan, Nabil Saleh, Roman Uzhachenko, Chengli Shen, Carlos Arteaga, Ann Richmond, Sangeetha M Reddy, Anna Vilgelm
Publikováno v:
Journal for ImmunoTherapy of Cancer. 11:e006019
BackgroundCyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy are a mainstay treatment for hormone receptor-positive breast cancer. While their principal mechanism is inhibition of cancer cell proliferation, preclinical a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::62bd9f7929ac9c56d8ed56e45fb642ea
https://doi.org/10.1136/jitc-2022-006019
https://doi.org/10.1136/jitc-2022-006019
Autor:
Caroline A. Nebhan, Vijaya Bharti, Holly Crandall, Rami N. Al-Rohil, Sheau-Chiann Chen, Ann Richmond, Mark C. Kelley, Rebecca L. Shattuck-Brandt, Emily Murray, Jamye F. O'Neal, Gregory D. Ayers, Rondi M. Kauffmann, Christopher Andrew Johnson, Chi Yan, Mary A. Hooks, Douglas B. Johnson, Ana Grau, Kimberly B. Dahlman, Anna E. Vilgelm
Publikováno v:
Clin Cancer Res
Purpose: Over 60% of patients with melanoma respond to immune checkpoint inhibitor (ICI) therapy, but many subsequently progress on these therapies. Second-line targeted therapy is based on BRAF mutation status, but no available agents are available
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d1b9286e7c86a7642df2e1572464ce9
https://doi.org/10.1158/1078-0432.ccr-19-1895
https://doi.org/10.1158/1078-0432.ccr-19-1895